Reconfigurable field-effect transistor (RFET) based biosensor

IN605947BActive Publication Date: 2026-10-14DELHI TECHNOLOGICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202411077386
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-10-11
Publication Date
2026-10-14
Estimated Expiration
2044-10-11

AI Technical Summary

Technical Problem

Conventional FET biosensors face challenges in detecting low concentrations of biomolecules and distinguishing between similar target molecules due to limited surface area and suboptimal electric field modulation, resulting in compromised sensitivity and selectivity.

Method used

A reconfigurable field-effect transistor (RFET) biosensor utilizing a silicon nanowire with a T-shaped control gate and dual cavity structure, enabling dynamic operation in n-mode and p-mode configurations, and providing a large surface area for biomolecule interaction and spatial separation of binding sites.

Benefits of technology

The RFET biosensor enhances sensitivity and selectivity by effectively modulating the electric field and increasing the surface area for biomolecule interaction, allowing precise detection and differentiation of target biomolecules, even at low concentrations.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to a reconfigurable field-effect (RFET) based biosensor (100). The biosensor (100) includes a silicon nanowire (102) functioning as a channel for the transistor, a T-shaped control gate (104) positioned above the silicon nanowire (102) and a dual cavity structure (106) located below the T-shaped control gate (104). The biosensor (100) is configured to detect changes in electrical signals corresponding to shifts in operating current or threshold voltage resulting from the interaction of one or more target biomolecules (B) with the silicon nanowire (102) within a region of the dual-cavity structure.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present disclosure relates, in general, to biosensors. Moreparticularly, it relates to a reconfigurable field-effect transistor (RFET) basedbiosensor utilizing silicon nanowire for biomolecule detection.BACKGROUND

[0002] The following description of the related art is intended to providebackground information pertaining to the field of the disclosure. This section mayinclude certain aspects of the art that may be related to various features of thepresent disclosure. However, it should be appreciated that this section be used onlyto enhance the understanding of the reader with respect to the present disclosure,and not as admission of the prior art.

[0003] Field-effect transistor (FET) based biosensors have emerged aspromising tools for detecting biomolecules in various biomedical andenvironmental applications. Their high sensitivity to surface charge changes makesthem ideal for real-time detection of biomolecular interactions, which is essentialfor diagnostics and monitoring. By leveraging the unique properties ofsemiconductor materials, particularly silicon, FET biosensors are capable oftranslating biomolecule interactions into measurable electrical signals.

[0004] However, traditional FET biosensors have encountered significantchallenges, particularly in detecting low concentrations of biomolecules anddistinguishing between similar target molecules. These limitations often result incompromised sensitivity and selectivity, which can hinder their effectiveness inapplications requiring high precision.

[0005] The primary limitations of conventional FET biosensors stem fromtheir design and interaction with biomolecules at the sensor surface. In typicaldesigns, the surface area available for biomolecule interaction is limited, and theelectric field modulation is often suboptimal. This reduces the efficiency of signaltransduction, especially when biomolecules are sparsely present or have similarcharge properties.

[0006] There is, therefore, a need for a simple, reliable, and effectivesolution to increase the available surface area for biomolecule binding, improvingthe interaction between target molecules and the sensor surface and ensuremodulation of the electric field.OBJECTS OF THE PRESENT DISCLOSURE

[0007] An object of the present disclosure is to provide a biosensor havingincreased sensitivity and selectivity for biomolecule detection by expanding thesurface area available for biomolecule interaction.

[0008] An object of the present disclosure is to provide a biosensor havingreconfigurable operational capability that allows the biosensor to dynamicallyswitch between n-mode and p-mode configurations, enabling the detection ofdifferent biomolecules.

[0009] An object of the present disclosure is to provide a biosensor thatenables modulation of the electric field effectively, to improve the biosensor'scapability to detect biomolecular interactions.

[0010] An object of the present disclosure is to provide a biosensor thatenables spatial separation of biomolecule binding sites for precise detection anddifferentiation of target biomolecules.SUMMARY

[0011] Aspects of the present disclosure relate to the technical field ofbiosensors. In particular, it relates to a reconfigurable field-effect transistor (RFET)based biosensor utilizing silicon nanowire for biomolecule detection.

[0012] According to an aspect, a reconfigurable field-effect transistor(RFET) based biosensor for biomolecule detection is disclosed. The biosensorincludes a silicon nanowire functioning as a channel for the transistor, a T-shapedcontrol gate positioned above the silicon nanowire and a dual cavity structurelocated below the T-shaped control gate. The biosensor is configured to detectchanges in electrical signals corresponding to shifts in operating current or thresholdvoltage resulting from the interaction of one or more target biomolecules with thesilicon nanowire within a region of the dual-cavity structure.

[0013] The T-shaped control gate may be configured to modulate an electricfield within the biosensor for detecting biomolecular interaction on the nanowiresurface.

[0014] The dual cavity structure may be configured to extend the availablesurface area for biomolecule interaction and immobilization.

[0015] In addition, the biosensor may include a reconfigurable circuitryconfigured to enable the biosensor to operate in both n-mode and p-modeconfigurations and adapt to detect the one or more target biomolecules based ontheir charging properties.

[0016] The silicon nanowire may exhibit a large surface-to-volume ratio toincrease sensitivity of the biosensor to a change in surface charge when the one ormore target biomolecules interact with the biosensor.

[0017] The dual cavity structure may be constructed in a manner to spatiallyseparate binding sites of one or more biomolecules for enhancing selectivity of thebiosensor for target biomolecules.

[0018] Further, the T-shaped control gate and dual cavity structure may bepositioned together in an arrangement to allow selective immobilization of specificbiomolecules.

[0019] Various objects, features, aspects and advantages of the inventivesubject matter will become more apparent from the following detailed descriptionof preferred embodiments, along with accompanying drawing figures in which likenumerals represent like components.BRIEF DESCRIPTION OF DRAWINGS

[0020] The accompanying drawings are included to provide a furtherunderstanding of the present disclosure and are incorporated in and constitute a partof this specification. The drawings illustrate exemplary embodiments of the presentdisclosure and, together with the description, serve to explain the principles of thepresent disclosure.

[0021] FIG. 1A illustrates a block diagram of the proposed reconfigurablefield-effect transistor (RFET) based biosensor, in accordance with an embodimentof the present disclosure.

[0022] FIG. 1B & FIG. 1C illustrate exemplary views of the reconfigurablefield-effect transistor (RFET) based biosensor, in accordance with an embodimentof the present disclosure.

[0023] FIG. 2 illustrates calibration of a reconfigurable field-effecttransistor (RFET) based biosensor with respect to experimental data of an existingstate of art.

[0024] FIGs. 3(a) - 3(d) illustrate electric field variations of thereconfigurable field-effect transistor (RFET) based biosensor in (a) N-mode and (b)P-mode configurations for neutral biomolecules and in (c) N-mode and (d) P-modeconfigurations for charged biomolecules, in accordance with an embodiment of thepresent disclosure.

[0025] FIGs. 4(a) - 4(d) illustrate drain current characteristics variations ofthe reconfigurable field-effect transistor (RFET) based biosensor in (a) N-mode and(b) P-mode configurations for neutral biomolecules and in (c) N-mode and (d) Pmodeconfigurations for charged biomolecules, in accordance with an embodimentof the present disclosure.

[0026] FIGs. 5(a) - 5(d) illustrate sensitivity analysis of the reconfigurablefield-effect transistor (RFET) based biosensor: (a) Ion sensitivity, (b) VTh sensitivityfor neutral biomolecules, (c) Ion sensitivity, and (d) VTh sensitivity for chargedbiomolecules, in accordance with an embodiment of the present disclosure.

[0027] FIGs. 6(a) - 6(b) illustrate selectivity comparison analysis of theTCG-DC SiNW RFET-based biosensor and existing SE R-Si NW SBT-basedbiosensor: (a) VTh selectivity, (b) Ion selectivity for neutral biomolecules, inaccordance with an embodiment of the present disclosure.DETAILED DESCRIPTION

[0028] The following is a detailed description of embodiments of thedisclosure depicted in the accompanying drawings. The embodiments are in suchdetails as to clearly communicate the disclosure. However, the amount of detailoffered is not intended to limit the anticipated variations of embodiments; on thecontrary, the intention is to cover all modifications, equivalents, and alternativesfalling within the spirit and scope of the present disclosure as defined by theappended claims.

[0029] Embodiment explained herein relates, in general, to biosensors.More particularly, it relates to a reconfigurable field-effect transistor (RFET) basedbiosensor utilizing silicon nanowire for biomolecule detection.

[0030] Referring to FIGs. 1A-1C, in an embodiment, proposedreconfigurable field-effect transistor (RFET) based biosensor 100 for biomoleculedetection is disclosed. The RFET based biosensor 100 can include a siliconnanowire 102 functioning as a channel for the transistor, a T-shaped control gate104 positioned above the silicon nanowire 102 and a dual cavity structure 106located below the T-shaped control gate 104. The biosensor 100 can be configuredto detect changes in electrical signals corresponding to shifts in operating current orthreshold voltage resulting from the interaction of one or more target biomoleculesB with the silicon nanowire 102 within a region of the dual-cavity structure 106.

[0031] In an exemplary embodiment, a Field-Effect Transistor (FET) is atype of transistor that controls the flow of current using an electric field. FETs usevoltage input at the gate to modulate the current between the source and drainterminals.

[0032] In an exemplary embodiment, a biosensor is an analytical device thatcombines a biological sensing element with a transducer to detect and measurespecific biomolecules or biochemical reactions.

[0033] In an exemplary embodiment, silicon nanowire is a one-dimensionalnanostructure made of silicon, with diameters typically in the range of 1-100 nm.

[0034] In an exemplary embodiment, a T-shaped control gate is a specificstructural design in field-effect transistors (FETs) that enhances the control over theelectric field and carrier movement within the device.

[0035] In an embodiment, the T-shaped control gate 104 can be configuredto modulate an electric field within the biosensor 100 for detecting biomolecularinteraction on the nanowire surface. The T-shaped control gate 104 can enhance thesensitivity of the biosensor 100 by concentrating the electric field in a way thatamplifies the response to biomolecular binding.

[0036] In an embodiment, the dual cavity structure 106 can be configuredto extend the available surface area for biomolecule interaction and immobilization.

[0037] In an embodiment, the biosensor 100 can include a reconfigurablecircuitry configured to enable the biosensor 100 to operate in both n-mode and pmodeconfigurations and can adapt to detect the one or more target biomolecules Bbased on their charging properties. This adaptability of operation in both n-modeand p-mode configurations can enables the biosensor 100 to optimize its detectionprocess in real-time, depending on the type of biomolecule being targeted. It canalso enhance the versatility of the biosensor 100 by allowing it to detect bothcharged and neutral biomolecules B as needed.

[0038] In an exemplary embodiment, in semiconductor devices,particularly field-effect transistors (FETs), n-mode (or n-type) and p-mode (or ptype)configurations refer to the type of charge carriers that dominate conduction.N-mode has electrons as the majority carriers and in p-type has holes as the majoritycarriers.

[0039] In an exemplary embodiment, biomolecules are any molecules thatare produced by living organisms and are essential for their structure, function, andregulation. Biomolecules can be proteins, nucleic acids, carbohydrates, lipids andmetabolites.

[0040] In an embodiment, the silicon nanowire 102 can exhibit a largesurface-to-volume ratio to increase sensitivity of the biosensor 100 to a change insurface charge when the one or more target biomolecules B interact with thebiosensor 100. The biomolecules B can attach to the surface of the silicon nanowire102, and their interaction can alter the local charge distribution, which can changethe electrical signals.

[0041] In an embodiment, the dual cavity structure 106 can be constructedin a manner to spatially separate binding sites of one or more biomolecules B forenhancing selectivity of the biosensor 100 for target biomolecules B The cavitiescan provide more precise spatial control over biomolecule binding sites, whichleads to greater selectivity by allowing the biosensor 100 to distinguish betweentarget and non-target biomolecules B. The arrangement of the dual cavity structure106 can enhance the biosensor's ability to isolate and detect specific biomoleculesB with high accuracy.

[0042] In an embodiment, the T-shaped control gate 104 and dual cavitystructure 106 can be positioned together in an arrangement to allow selectiveimmobilization of specific biomolecules B.

[0043] In an embodiment, when biomolecules B, such as proteins or DNA,bind to the surface of the silicon nanowire 102 in the dual-cavity region, they cancause changes in the local charge distribution, affecting the nanowire's conductivity.This change can be detected by monitoring shifts in the operating current (Ion) orthreshold voltage (VTh) of the FET. The T-shaped gate can ensure effectivemodulation of the electric field across the binding sites, improving the detection ofthese shifts. The reconfigurable circuitry can further allow fine-tuning of thebiosensor's detection mechanism, leading to higher accuracy and reliability invarious biomolecular detection scenarios.

[0044] In an embodiment, the FET based biosensor 100 can include source108 and drain 110 terminals. The current can flow between the source 108 and drain110 through the silicon nanowire channel 120. The source 108 and drain 110 can bemade of nickel silicide (NiSi) for higher conductivity.

[0045] In an embodiment, the silicon nanowire 102 can be surrounded by alayer, gate oxide 112. This insulating layer can isolate the gate from the nanowire102, allowing for effective electric field modulation without direct current flow.

[0046] In an exemplary embodiment, gate oxide is the insulating layerbetween the gate and the semiconductor channel and used for controlling the flowof current in the transistor. It is made from silicon dioxide (SiO₂) or high-k dielectricmaterials.

[0047] In an embodiment, a program gate 114 can be positioned at the right,this gate can likely play a role in biasing the biosensor to dynamically operate in nmodeor p-mode configuration and enhancing the control gate's 104 modulation,contributing to sensitivity and signal processing. In an exemplary embodiment, aprogram gate can be an additional or specialized gate used to fine-tune or controlthe operation of the sensor beyond the control gate 104.

[0048] In an embodiment, a buried oxide layer 116 and a silicon substrate118 can provide structural support and insulation. The buried oxide layer 116 canseparate the active sensing region from the substrate 118, reducing interference. Inan exemplary embodiment, a buried oxide layer is a layer of silicon dioxide (SiO₂)that is embedded between layers of silicon in a semiconductor device.

[0049] In an embodiment, titanium dioxide (TiO2) layers can be used forenhancing the gate's electric field modulation capabilities, as TiO2 is a highdielectric material.

[0050] Referring to FIG. 2 illustrating a relationship between drain current(I_D) and gate voltage (V_GS) for a reconfigurable field-effect transistor (RFET)based biosensor operating in both n-mode and p-mode configurations. FIG.2. showscomparison of simulation results (represented by triangles) and experimental data(represented by squares), showing how the transistor's current changes in responseto varying gate voltages. The X-axis can represent the voltage applied to the gateterminal of the RFET, which controls the flow of current between the source anddrain. It can range from -3V to +3V. The Y-axis can represent the current flowingfrom the drain to the source, measured in amps per micrometer (A / μm). The valuescan range logarithmically from 1E-16 A / μm to 1E-4 A / μm. V_DS = |1V| canindicate that a fixed drain-source voltage of 1V is applied during the measurements.The left side of the graph, where V_GS is negative can represent p-mode operation.In this mode, a negative gate voltage can enhance the conductivity of holes (positivecharge carriers), leading to an increase in the drain current. The drain current canincrease significantly as the gate voltage becomes more negative, with the I_Drising from approximately 1E-16 A / μm to 1E-6 A / μm as V_GS moves from 0V to-3V. The right side of the graph, where V_GS is positive can represents n-modeoperation. In this mode, a positive gate voltage can enhance the flow of electrons(negative charge carriers), resulting in increased drain current. As the gate voltagebecomes more positive, the drain current can rise, showing an increase from around1E-16 A / μm to 1E-6 A / μm as V_GS moves from 0V to +3V. The triangles can bedata points showing the drain current predicted by simulation models. Thesimulation can closely follow the trend in both p-mode and n-mode, showing anexponential rise in current as the gate voltage moves farther from zero in eitherdirection. The experimental da ta can largely match the simulation results, althoughthere are minor deviations. The general behavior of increasing drain current withhigher positive or negative gate voltage can be confirmed in the experimental data.

[0051] Referring to FIGs. 3(a) - 3(d), in an embodiment, illustrate thevariation of electric field (in MV / μm) along the device length (in nm) for areconfigurable field-effect transistor (RFET) based biosensor. FIGs. 3(a) - 3(d)show the analyzation of the impact of different parameters on the electric fielddistribution within the device, including the dielectric constant (K) and the freecharge density (Nf). FIG. 3(a) shows the change in the electric field along the lengthof the silicon nanowire or channel under n-mode operation when varying thedielectric constant (K). The dielectric constant can have different values, where K=1can represent the baseline with lowest electric field and as the dielectric constantincreases (K = 2.5, 6.3, 8, and 12), the electric field's peak value can increase atcertain regions along the channel. The electric field can become more pronouncedas K increases, suggesting improved charge control by the gate due to higherdielectric constant materials, which can enhance the sensor's sensitivity in thismode. FIG. 3(b) shows how the electric field changes along the device length underp-mode operation as the dielectric constant (K) increases. The electric field canexhibit a similar trend as in n-mode of operation, with higher K values leading tostronger electric fields, particularly in specific regions of the channel. The electricfield distribution can peak around the same regions as in the n-mode, showing howdielectric constant changes affect both modes similarly. FIG. 3 (c) shows the effectof free charge density (Nf) on the electric field in n-mode operation. The free chargedensity can have different values, where Nf=0 can indicate no additional charge,resulting in a baseline electric field, where Nf has a positive charge density of 5x1012cm-2 it can slightly increase the electric field along the channel and where Nf has anegative charge density of -5x1012 cm-2 it can reduce the electric field showing thatthe sign and magnitude of free charges can have an impact on the electric fielddistribution, and by extension, the device's performance in detecting biomolecules.FIG. 3(d) shows the effect of free charge density on the electric field in p-modeoperation. The electric field can trend similarly to FIG. 3(c), where the positivecharge density can increase the electric field, while negative charge density canreduce it and in n-mode, the electric field can be significantly affected by the freecharge density, implying that both modes can be responsive to variations in chargedistribution along the channel.

[0052] Referring to FIGs. 4(a) - 4(d), in an embodiment, represent therelationship between drain current (I_DS) and control gate voltage (V_CG) for areconfigurable field-effect transistor (RFET) biosensor in different conditions.FIGS. 4(a) - 4(d) can be divided into n-mode and p-mode, showing how thedielectric constant (K) and free charge density (Nf) affect the device's performance.FIG. 4(a) shows the drain current (I_DS) as a function of the control gate voltage(V_CG) in n-mode operation. The dielectric constant can have different values,when K increases from 1 to 12, the drain current can significantly increase,especially at higher control gate voltages and for lower K values (1, 2.5), the currentcan begin to increase only after a higher V_CG, but for higher K values (6.3, 8, 12),the current can increase earlier, indicating a more sensitive response due to thehigher dielectric constant. FIG. 4(b) shows the relationship between drain currentand control gate voltage in p-mode operation. For all values of K, the drain currentcan decrease as the control gate voltage increases (positive V_CG). As K increases,the overall drain current can be higher at negative gate voltages, indicating that ahigher dielectric constant can improve the device's current response in p-mode andmake it more sensitive. FIG. 4(c) shows the effect of free charge density (Nf) ondrain current in n-mode operation for a fixed K value of 12, where when Nf = 0 thebaseline can have no additional charge, where Nf has a positive charge density of5x1012 cm-2 it can lead to a higher drain current, indicating that positive charges canenhance the current and where Nf has a negative charge density of -5x1012 cm-2 canresult in a lower current, showing that negative charges can reduce the drain current.FIG. 4(d) shows the effect of free charge density affects the drain current in p-modeoperation, where Nf has a positive charge density of 5x1012 cm-2 can lead to a higherdrain current at lower control gate voltages, however it can reduce the current athigher voltages and Nf has a negative charge density of -5x1012 cm-2 it can decreasethe drain current, particularly at lower control gate voltages.

[0053] Referring to FIGs. 5(a) - 5(d), in an embodiment, represent thesensitivity of a RFET-based biosensor in n-mode and p-mode as a function ofdielectric constant and biomolecule charge density. The sensitivity can berepresented in terms of I_ON Sensitivity (current sensitivity) and V_TH Sensitivity(threshold voltage sensitivity). FIG. 5(a) shows the relationship between I_ONSensitivity and dielectric constant. In n-mode, the current sensitivity can increasedramatically as the dielectric constant increases from 6.3 to 12, implying that the nmodebiosensor can become highly sensitive to changes in current when K is largeand in p-mode, the increase in I_ON sensitivity can be much smaller, remainingrelatively constant across different values of K. FIG. 5(b) shows the V_TH(threshold voltage) sensitivity as a function of the dielectric constant. In n-mode,the V_TH sensitivity can increase with increasing K, showing a greater dependenceon K compared to p-mode, implying that n-mode is more sensitive to dielectricconstant changes and in p-mode, the sensitivity can increase more gradually as Kincreases, but it can be still lower than in n-mode. FIG. 5(c) shows the I_ONSensitivity as a function of biomolecule charge density. In n-mode, the I_ONsensitivity can increase with the magnitude of biomolecule charge density, implyingthat the sensor can be more sensitive to a higher density of biomolecules. In p-mode,the sensitivity can remain much lower and decrease slightly as the charge densityincreases, indicating that p-mode can be less sensitive to biomolecule chargedensity compared to n-mode. FIG. 5(d) shows the V_TH sensitivity as a functionof biomolecule charge density. In n-mode, the threshold voltage sensitivity candecrease slightly as the biomolecule charge density changes from negative topositive and can increase again at the extremes of biomolecule charge density. In pmode,the V_TH sensitivity can remain much lower and more stable, showing onlyslight variations with changes in biomolecule charge density.

[0054] Referring to FIGS. 6(a) - 6(b), in an embodiment, represents thecomparison of performance of two types of silicon nanowire-based RFETs-oneutilizing a T-shaped control gate with a dual-cavity structure and the other areference silicon nanowire RFET. Both devices can be evaluated in n-mode and pmodeconfigurations and can be selectivity plotted against the dielectric constant(K) of the sensing medium. FIG. 6(a) shows the selectivity of the T-shaped controlgate with dual-cavity structure in N-mode, showing the highest selectivity acrossall dielectric constants, starting at around 0.6 and gradually decreasing with anincrease in K and the reference silicon nanowire RFET displays a much lowerselectivity, consistently decreasing as the dielectric constant increases. Both thesilicon nanowire-based RFETs can show low selectivity, with similar behavioracross the dielectric constant range, but the TCG-DC structure consistentlyperforms slightly better. FIG. 6(b) shows the selectivity of the T-shaped control gatewith dual-cavity structure in N-mode is again the highest initially at around 1.2 butdecreases as the dielectric constant increases and reference silicon nanowire RFETshows lower selectivity in comparison but with a similar downward trend. Both thesilicon nanowire-based FETs can show reduced selectivity overall, but the T-shapedcontrol gate with dual-cavity structure can outperform the reference device slightlyin the same dielectric constant range.

[0055] Thus, reconfigurable field-effect transistor (RFET)-based biosensorfeaturing a T-shaped control gate and dual cavity structure, which significantlyenhances electric field modulation, sensitivity, and selectivity for biomoleculedetection. The T-shaped gate allows for precise control over the electric field,improving the detection accuracy of low-concentration target analytes, while thedual cavity structure provides a larger surface area for biomolecule interaction,enabling simultaneous binding and minimizing non-specific interactions.Additionally, the biosensor is designed to be compatible with complementary metaloxide-semiconductor (CMOS) technology, facilitating integration with on-chipelectronics for portable, scalable, and cost-effective applications.

[0056] While the foregoing describes various embodiments of theinvention, other and further embodiments of the invention may be devised withoutdeparting from the basic scope thereof. The scope of the invention is determined bythe claims that follow. The invention is not limited to the described embodiments,versions or examples, which are included to enable a person having ordinary skillin the art to make and use the invention when combined with information andknowledge available to the person having ordinary skill in the art.ADVANTAGES OF THE PRESENT DISCLOUSRE

[0057] The present disclosure provides a RFET based biosensor withintegration of a dual-cavity structure and T-shaped control gate that improve thedetection of charged biomolecules and an increased surface area provided by thedual cavities, combined with the precise modulation of the electric field, allowingthe biosensor to detect even minute changes in charge distribution caused by thebinding of charged molecules.

[0058] The present disclosure provides a RFET based biosensor withreconfigurable circuitry to allow the biosensor to switch between n-mode and pmodeconfigurations based on the applied bias, making it adaptable to detect bothcharged and neutral biomolecules.

[0059] The present disclosure provides a RFET based biosensor having asilicon nanowire, with its large surface-to-volume ratio enhancing the biosensor'sability to detect small changes in surface charge when biomolecules interact withit, leading to greater sensitivity.

[0060] The present disclosure provides a RFET based biosensor with a dualcavity structure that provides spatial separation of biomolecule binding sites,improving the selectivity of the biosensor through selective immobilization of targetbiomolecules and reduced non-specific interactions.

Claims

1. A reconfigurable field-effect transistor (RFET) based biosensor (100) for biomolecule detection, said biosensor (100) comprising: a silicon nanowire (102 ) functioning as a channel for the transistor; a T-shaped control gate (104) positioned above the silicon nanowire (102); and a dual cavity structure (106) located below the T-shaped control gate (104); wherein the biosensor (100) is configured to detect changes in electrical signals corresponding to shifts in operating current or threshold voltage resulting from the interaction of one or more target biomolecules (B) with the silicon nanowire (102) within a region of the dual-cavity structure (106).

2. The biosensor (100) as claimed in claim 1, wherein the T-shaped control gate (104) is configured to modulate an electric field within the biosensor (100) for detecting biomolecular interaction on the nanowire surface.

3. The biosensor (100) as claimed in claim 1, wherein the dual cavity structure (106) is configured to extend the available surface area for biomolecule interaction and immobilization.

4. The biosensor (100) as claimed in claim 1, wherein the biosensor (100) comprises a reconfigurable circuitry configured to enable the biosensor (100) to operate in both n-mode and p-mode configurations and adapt to detect the one or more target biomolecules (B) based on their charging properties.

5. The biosensor (100) as claimed in claim 1, wherein the silicon nanowire (102) exhibits a large surface-to-volume ratio to increase sensitivity of the biosensor (100) to a change in surface charge when the one or more target biomolecules (B) interact with the biosensor (100).

6. The biosensor (100) as claimed in claim 1, wherein the dual cavity structure (106) is constructed in a manner to spatially separate binding sites of one or more biomolecules (B) for enhancing selectivity of the biosensor (100) for target biomolecules (B).

7. The biosensor (100) as claimed in claim 1, wherein the T-shaped control gate (104) and dual cavity structure (106) are positioned together in an arrangement to allow selective immobilization of specific biomolecules (B).